Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada

Clinical Therapeutics

Volumn 31, Issue 3, 2009, Pages 657-667

  Charles, Meaghan E St ^a   Sadri, Hamid ^b   Minshall, Michael E ^a   Tunis, Sandra L ^a  

^a IQVIA   (United States)

^b Medtronic of Canada Ltd   (Canada)

Author keywords

continuous subcutaneous insulin infusion; cost effective; insulin; modeling; multiple daily injections; type 1 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; INSULIN;

ANGINA PECTORIS; ARTICLE; BLINDNESS; CANADA; CATARACT; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DIABETIC RETINOPATHY; DOSAGE SCHEDULE COMPARISON; DRUG COST; FOOT ULCER; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; LIFE EXPECTANCY; MICROALBUMINURIA; MULTIPLE DRUG DOSE; PERIPHERAL NEUROPATHY; PERIPHERAL VASCULAR DISEASE; PROTEINURIA; QUALITY OF LIFE; RETINA MACULA EDEMA; SENSITIVITY ANALYSIS; STROKE; TREATMENT OUTCOME; VISUAL IMPAIRMENT;

ADULT; BIOLOGICAL MARKERS; CANADA; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; FEMALE; FINANCING, GOVERNMENT; HEALTH CARE COSTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; LIFE EXPECTANCY; MALE; MARKOV CHAINS; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 64849083167     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.03.013     Document Type: Article

References (47)

1. Juvenile Diabetes Research Foundation Australia. Diabetes Statistics. Juvenile Diabetes Research Foundation Australia 2006. http://www.jdrf.org.au/s/media/documents/factsheets/what_is_type_1_diabetes.pdf Accessed May 15, 2008
2. Canadian Diabetes Association. Diabetes facts. http://www.diabetes.ca/about-diabetes/what/facts Accessed November 26, 2007
3. Roper N.A., Bilous R.W., Kelly W.F., et al. Excess mortality in a population with diabetes and the impact of material deprivation: Longitudinal, population based study. BMJ 322 (2001) 1389-1393
4. Lenhard M.J., and Reeves G.D. Continuous subcutaneous insulin infusion: A comprehensive review of insulin pump therapy. Arch Intern Med 161 (2001) 2293-2300
5. Pickup J., Mattock M., and Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: Meta analysis of randomised controlled trials. BMJ 324 (2002) 705
6. Weissberg-Benchell J., Antisdel-Lomaglio J., and Seshadri R. Insulin pump therapy: A meta-analysis. Diabetes Care 26 (2003) 1079-1087
7. Hoogma R.P., Hammond P.J., Gomis R., et al., for the 5-Nations Study Group. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: Results of the 5-Nations Trial. Diabet Med 23 (2005) 141-147
8. Colquitt J.L., Green C., Sidhu M.K., et al. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. Health Technol Assess 8 (2004) 1-171
9. Scuffham P., and Carr L. The cost-effectiveness of continuous subcutaneous insulin infusion compared with multiple daily injections for the management of diabetes. Diabet Med 20 (2003) 586-593
10. Roze S., Valentine W.J., Zakrzewska K.E., and Palmer A.J. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of type 1 diabetes in the UK. Diabet Med 22 (2005) 1239-1245
11. Palmer A.J., Roze S., Valentine W.J., et al. The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin 20 Suppl 1 (2004) S5-S26
12. Palmer A.J., Roze S., Valentine W.J., et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 20 Suppl 1 (2004) S27-S40
13. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [published correction appears in Lancet. 1999;354:602]. Lancet 352 (1998) 837-853
14. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
15. Nathan D.M., Cleary P.A., Backlund J.Y., et al., for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2653
16. Miller C.D., Phillips L.S., Tate M.K., et al. Meeting American Diabetes Association guidelines in endocrinologist practice. Diabetes Care 23 (2000) 444-448
17. Bank of Canada. Inflation calculator. http://www.bankofcanada.ca/en/rates/inflation_calc.html Accessed May 1, 2008
18. Ontario Case Costing Initiative (OCCI). Hyperbaric oxygen therapy for non-healing ulcers in diabetes mellitus. Ontario Ministry of Health and Long-Term Care 2005. http://www.health.gov.on.ca/english/providers/program/ohtac/tech/reviews/pdf/rev_hypox_081105.pdf Accessed December 20, 2007
19. O'Brien J.A., Patrick A.R., and Caro J.J. Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Serv Res 3 (2003) 7
20. Levy A.R., Briggs A.H., Demers C., and O'Brien B.J. Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. Am Heart J 142 (2001) 537-543
21. Coyle D., Palmer A., and Tam R. Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada. PharmacoEconomics 20 Suppl 1 (2003) 31-42
22. Medical Procedure List. Alberta Health Care Insurance Plan. http://www.health.alberta.ca/documents/SOMB-medical-procedures.pdf Accessed March 10, 2009
23. Curtis J.R., To T., Muirhead S., et al. Recent trends in hospitalization for diabetic ketoacidosis in Ontario children. Diabetes Care 25 (2002) 1591-1596
24. Nova Scotia Prescription, Canadian Trade Index. Annual pricing. http://www.ctidirectory.com Accessed December 2, 2007
25. Nova Scotia Pharmacy: Pricing with a 30-day supply assumption. Canadian Trade Index. 2007. http://www.ctidirectory.com Accessed December 2, 2007
26. Allied Health Services Schedule of Benefits. http://www.health.alberta.ca/professionals/allied-servicesschedule.html Accessed March 10, 2009
27. Nova Scotia Podiatrist Fees. http://www.health.alberta.ca/professionals/allied-services-schedule.html Accessed March 10, 2009
28. Alberta WCB Physician Fee Schedule. Ministry of Health, Province of Alberta. http://www.web.ab.ca/pdfs/providers/WCB_Fee_Schedule_Alberta_Physicians.pdf/html Accessed January 15, 2008
29. Regranex 15 mg tube 0.01%. Canada Rx 2007. http://www.canadadrugs.com/prescription/product/regranex+gel/11194 Accessed December 19, 2007
30. Medtronic insulin pump supply price list for Canada. http://minimed.ca/CanadaCategory.aspx Accessed March 11, 2009
31. Ontario Ministry of Health and Long Term Care. Ontario drug benefit: The program. 2007. http://www.health.gov.on.ca/english/providers/program/drugs/edition-40.html Accessed April 1, 2008
32. Ontario Health Insurance Plan (OHIP): Schedule of Benefits and Fees. 2007. http://www.health.gov.on.ca/english/providers/program/ohip/sob/sob_mn.html Accessed March 10, 2009
33. Clarke P., Gray A., and Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making 22 (2002) 340-349
34. Tengs T.O., and Wallace A. One thousand health-related quality-of-life estimates. Med Care 38 (2000) 583-637
35. Begg S., Vos T., Barker B., et al. The Burden of Disease and Injury in Australia. 2003 (2007), Australian Institute of Health and Welfare. www.aihw.gov.au.publications Accessed March 4, 2008
36. Carrington A.L., Mawdsley S.K., Morley M., et al. Psychological status of diabetic people with or without lower limb disability. Diabetes Res Clin Pract 32 (1996) 19-25
37. Guidance on the Use of Long-Acting Insulin Analogues for the Treatment of Diabetes-Insulin Glargine (2002), National Institute for Clinical Excellence, London, UK Technology Appraisal Guidance No. 53
38. American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 27 (2004) 2262-2265
39. Canadian Agency for Drugs and Technologies in Health. Guidelines for the Economic Evaluation of Health Technologies: Canada. 3rd ed (2006), CADTH Publications, Ottawa, Ontario, Canada
40. Linkeschova R., Raoul M., Bott U., et al. Less severe hypoglycaemia, better metabolic control, and improved quality of life in type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consecutive patients followed for a mean of 2 years. Diabet Med 19 (2002) 746-751
41. DeWitt D.E., and Hirsch I.B. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review. JAMA 289 (2003) 2254-2264
42. Bode B.W., Sabbah H.T., Gross T.M., et al. Diabetes management in the new millennium using insulin pump therapy. Diabetes Metab Res Rev 18 Suppl 1 (2002) S14-S20
43. Bruttomesso D., Pianta A., Crazzolara D., et al. Continuous subcutaneous insulin infusion (CSII) in the Veneto region: Efficacy, acceptability and quality of life. Diabet Med 19 (2002) 628-634
44. Currie C.J., Morgan C.L., Poole C.D., et al. Multivariate models of healthrelated utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 22 (2006) 1523-1534
45. In: Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. (Eds). Cost-Effectiveness in Health and Medicine (1996), Oxford University Press, New York, NY
46. Halpern E.F., Weinstein M.C., Hunink M.G., and Gazelle G.S. Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients. Med Decis Making 20 (2000) 314-322
47. Laupacis A., Feeny D., Detsky A.S., and Tugwell P.X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146 (1992) 473-481